# A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer

> **NCT03803761** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic Breast Carcinoma
- Metastatic Malignant Neoplasm in the Brain
- Prognostic Stage IV Breast Cancer AJCC v8

## Interventions

- **DRUG:** Copanlisib
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT03803761
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-02-13
- **Primary completion:** 2022-02-19
- **Final completion:** 2022-02-19
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Inadequate accrual rate
- **Last updated:** 2023-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03803761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03803761, "A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03803761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*